EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK
Abstract
Authors
Matthew Tucker Johannes Pöhlmann Kristin Grabe-Heyne Annelie Wagner Anja Rasch Mondher Toumi Muhammad K. Nisar Richard F. Pollock